Interestingly, although itolizumab-treated PBMCs co-cultured with tumor cell lines show similar CD6 downmodulation (Supplementary Figure 3A), the functional responses are different in each condition, suggesting that CD318 and itolizumab decrease CD6 expression by a different mechanism that could trigger alternative outcomes. The gene discussed is CD6; the disease is neoplasm.